Best Blue Chip Stocks this May 2026 in the UK

Diageo stands out as a beverages company with a robust market capitalization and a strong dividend yield, making it an attractive option for investors seeking reliable income from financially healthy companies. Despite its top analyst rating of A-, recent challenges have emerged; inflation has pressured consumers to shift away from Diageo's premium offerings, impacting sales. Investors should weigh these dynamics as they consider the potential for consistent payouts amid current market conditions.

Diageo is struggling due to inflation, which has led consumers to downgrade from its premium brands or cut back on spending. Additionally, US tariffs have negatively impacted exports of its Canadian whisky and Don Julio tequila.

As of December 31, 2025, Berkshire Hathaway holds 227,750 shares of Diageo, valued at approximately $19.65 million, representing 0.01% of their portfolio.

Rentokil Initial stands out as a top-rated pest control and facilities management company, making it one of Europe’s best stock ideas. With a dividend yield of 1.76%, it offers a reliable income stream, despite a challenging one-year return of -24.99%. Long-term growth drivers in the pest control market present an encouraging outlook for investors seeking stability and potential upside.

Yes, Rentokil Initial has strong long-term growth drivers, with the global pest control market expected to grow at a 6.2% CAGR through 2032.

Given a 90-day horizon and above-average risk tolerance, Ganfeng Lithium is rated a 'Strong Sell'.

Analysts have mixed opinions on Crown Castle: 25% recommend a Strong Buy, 38% recommend Buy, and 38% suggest Hold, with no recommendations for Sell.

Tetra Tech (TTEK) has a consensus rating of Buy from three analysts.

AstraZeneca stands out as a top blue-chip stock in the UK pharmaceuticals sector, renowned for its robust market capitalization. Despite recent analyst downgrades and challenges with its China subsidiary, the company boasts a promising pipeline and strategic acquisitions, earning a solid B+ rating from analysts. This combination of strengths positions AstraZeneca as a noteworthy consideration for long-term investors, particularly those focused on momentum, as indicated by its favorable scores in this area.

The stock is declining due to recent analyst downgrades and concerns about its operations in China, despite a strong product pipeline.

AstraZeneca has a Zacks Rank of #3 (Hold) and a Momentum Style Score of A, with shares up 5.5% in the last month and positive earnings revisions for fiscal 2026.

The consensus rating for AstraZeneca is 'Buy', with 20 analysts recommending a buy, 2 suggesting a sell, and 2 advising to hold.

Rolls-Royce Holdings is recognized for its strong position in the aerospace and defense sectors, anticipated to outperform by 2026, thanks to its diversified exposure to both commercial aerospace and defense. Despite facing challenges from cyclical travel demand and unforeseen events like the pandemic, the company's diversified strategy offers resilience and growth potential. With an analyst rating of A-, it remains a compelling option for investors looking for stability in a fluctuating market.

The stock is declining due to cyclical travel demand and external factors like the pandemic, which negatively impact engine flying hours and revenue.

Rolls-Royce benefits from its diversification in commercial aerospace and defense, allowing it to capitalize on multiple growth opportunities.

With a solid market position in media and information services, RELX presents an attractive investment opportunity, particularly for those interested in dividend-growth stocks. Despite a challenging year with a 1-year return of -31.54%, the company has reaffirmed its full-year guidance, bolstered by strong revenue growth and increasing demand for AI tools. Analysts maintain a positive outlook, with a median price target of $26.00 and upgrades from firms like Citigroup and Barclays, reflecting their confidence in RELX's long-term potential.

Yes, RELX has shown strong underlying revenue growth and demand for AI tools, reaffirming its guidance for continued growth in revenue and operating profit.

RELX reported a full-year revenue of £9.6 billion, with a 7% underlying growth and a 9% increase in operating profit to £3.3 billion, improving its margins from 33.9% to 34.8%.

Glencore, a leading mining and commodities company, showcased impressive performance in Q1 2026, earning strong analyst recognition with a consensus rating of "Buy" from 19 analysts. With an exceptional one-year return of 112.24% and a solid five-year return of 80.50%, it presents an attractive option for investors looking for value, as it may currently be undervalued with a Value Score of A. The company also offers a dividend yield of 1.59%, enhancing its appeal as a reliable income source for investors focused on financially healthy firms.

Glencore PLC is considered a good long-term investment, with a Value Score of A indicating it may be undervalued and a Growth Score of B suggesting strong financial health and growth potential.

The consensus rating for Glencore is 'Buy', with 14 analysts recommending a purchase, 5 suggesting to hold, and none advising to sell.

Glencore aims to produce over 1 million tonnes of copper annually by 2028, targeting 1.6 million tonnes by 2035, supported by a strong portfolio of growth options.

Unilever stands out as a reliable blue-chip stock in the consumer goods sector, boasting an analyst rating of S-. The company's underlying sales increased by 3.5% in 2025, driven by a combination of volume and price growth, highlighting its capacity to adapt and thrive in a competitive market. With Power Brands leading the charge at 4.3% sales growth, investors can feel confident in Unilever's strategic positioning and commitment to delivering consistent performance.

Unilever's 2025 results indicate a 3.5% growth in underlying sales, driven by 1.5% from volume and 2.0% from price increases.

Analysts have an average price target of $65.55 for Unilever, suggesting a potential upside of 13.94% from its current price of $57.53.

HSBC Holdings stands out as a leading blue-chip stock in the UK, recognized for its solid financial foundation and attractive growth potential. With a remarkable 1-year return of 58.91% and a 5-year return of 200.82%, it appeals to both value and income-focused investors, boasting a dividend yield of 4.64%. Although recent analyst ratings show mixed sentiments, the consensus remains a "Buy," reflecting confidence in HSBC's ability to outperform the market and deliver consistent payouts.

The consensus rating for HSBC is 'Buy', with 7 analysts recommending a buy, 1 suggesting a sell, and 9 advising to hold.

HSBC Holdings plc has a Value Score of B, indicating it is a solid choice for value investors, with good financial health and growth prospects.

HSBC's internal fair value is £13.53, suggesting it is slightly undervalued, though its current P/E ratio of 14.6x exceeds the European banks average of 11.2x.

Antofagasta stands out as a leading player in the industrial metals and mining sector, boasting a significant market capitalization among UK blue-chip companies. With a strong one-year return of 123.40% and a dividend yield of 1.20%, it presents an attractive option for income-focused investors. However, recent analyst ratings, including downgrades from Morgan Stanley and Barclays, suggest a more cautious approach, with a consensus rating leaning towards "Neutral."

Antofagasta has a consensus rating of 'Neutral' from 21 analysts, with 5 recommending a buy, 6 suggesting a sell, and 10 advising to hold.

East Star Resources has a consensus rating of 'Strong Buy' from 1 analyst, who recommends buying the stock.

Based on a 90-day horizon and above-average risk tolerance, Ganfeng Lithium is rated as a 'Strong Sell'.

The average 12-month price target for Defiance Silver is 0.8000 CAD, according to 1 analyst.